Bloomberg Talks
Novo Nordisk CEO Talks Weight Loss Drug Supply
May 2, 2024
Novo Nordisk CEO discusses scaling up production of weight-loss drug Wegovy with Bloomberg journalists. Topics include manufacturing capacity, unit costs, pricing strategies in drug production, long-term use of weight loss drugs, administration routes, and personalized medicine.
12:05
Episode guests
AI Summary
AI Chapters
Episode notes
Podcast summary created with Snipd AI
Quick takeaways
- Novo Nordisk is expanding drug supply to meet rising demand and aims to treat millions more patients with increased manufacturing capacity.
- The company is balancing costs and affordability by reducing list prices, increasing rebates, and considering patient preferences for different drug formulations.
Deep dives
Novo Nordisk Scaling Up Production and Capacity
Novo Nordisk, led by CEO Lars Frogaard-Yorgensen, is addressing the increasing demand for their products, particularly witnessing a rise in new patient starts weekly from 5-6,000 to 27,000. The company is focusing on ensuring continuous patient treatment by expanding manufacturing and offering higher doses. With additional investment of $6.4 billion in manufacturing capacity, Novo Nordisk aims to treat millions more patients and reduce unit costs through improved scale.
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
